Publication | Closed Access

Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population

MedicineImmunologyImmune Checkpoint InhibitorFirst-line TreatmentReal World PopulationCancer TreatmentOncologyRadiation OncologyLung Cancer